OBR Green Articles (ASCO Conference Coverage)

article

June 2017Edition

Right target, right patient, right time... This year at ASCO, targeted therapies held the spotlight. We take a look at 5 pivotal studies from the meeting and pose key questions that clinicians may consider with regards to outcomes and the data presen...

article

June 2017Edition

In a first, patient-reported outcomes (PRO) for symptom reporting was shown to increase survival in cancer patients at ASCO 2017. Studies looking at PRO, and psychologic interventions and support, were presented in the plenary session. Real progress ...

article

June 2017Edition

ASCO 2017 is behind us, but the clinical legacy will no doubt live on. Our round-up includes news on tumor agnostics, larotrectinib hitting 17 different cancer types, Alectinib in ALK-positive advanced NSCLC, and a pembro/IDO-inhibitor combo that loo...